Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Issue 2 (May 2015)

• Record Type: Journal Article
• Authors: Ghatalia, Pooja; Morgan, Charity J.; Je, Youjin; Nguyen, Paul L.; Trinh, Quoc-Dien; Choueiri, Toni K.; Sonpavde, Guru
• Is Part Of: Critical reviews in oncology/hematology. Volume 94:Issue 2(2015)
• Page Start: 228
• Page End: 237
• Publication Date: 2015-05
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2014.12.008
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <p id="spar0005">A systematic review and meta-analysis was conducted to determine the relative risk (RR) of congestive heart failure (CHF) associated with approved multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). Eligible studies included randomized trials comparing arms with and without an FDA-approved VEGFR TKI. Statistical analyses calculated the relative risk (RR) and 95% confidence intervals (CI). A total of 10, 647 patients from 16 phase III trials and 5 phase II trials were selected. All grade CHF occurred in 138 of 5752 (2.39%) patients receiving VEGFR TKIs and 37 of 4895 (0.75%) patients in the non-TKI group. High-grade CHF occurred in 17 of 1426 (1.19%) patients receiving VEGFR TKIs and 8 of 1232 (0.65%) patients in the non-TKI group. The RR of all grade and high-grade CHF for the TKI vs. no TKI arms was 2.69 (<italic>p</italic> &lt; 0.001; 95% CI: 1.86 to 3.87) and 1.65 (<italic>p</italic> = 0.227, 95% CI: 0.73 to 3.70), respectively. The RR of relatively specific TKIs (axitinib) was similar to relatively non-specific TKIs (sunitinib, sorafenib, vandetanib, pazopanib).</p> </sec> </abstract>